(Q42948972)

English

Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab

scientific article published on 2 August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Giuseppe Giaccone

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

author name string

Ronan J Kelly

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Corey Carter

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

language of work or name

0 references

publication date

2 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

e507-10

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

HER2/neu expression in malignant lung tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpres

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/20679607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2010.29.3126

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42948972&oldid=1974314872"